NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma (ANBL0531)
Study ID: ANBL0531
NCT Number: NCT00499616
Children's Oncology Group (COG)
Submitted in collaboration with the NCTN/NCORP Data Archive
Trial Title: NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma (ANBL0531)
Trial Description: RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma cells become more like normal cells, and grow and spread more slowly. Giving combination chemotherapy before surgery may make the tumor smaller and make it more likely that the tumor can be surgically removed. It is not yet known what is the minimal amount of chemotherapy needed to achieve sufficient tumor shrinkage to control intermediate risk neuroblastoma and prevent tumor recurrence or metastases.
PURPOSE: This phase III trial is designed to reduce therapy for patients with favorable biology intermediate risk neuroblastoma by decreasing the number of chemotherapy cycles administered and by allowing for up to 50% residual tumor volume for patients with localized disease.
Clinical data presented in the following publication(s):
Disease type(s): CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
Clinical Dataset(s) included:
• NCT00499616-D1 (PMID 30444686): There are five datasets (-D1 through -D5) for the ANBL0531 primary publication 30444686, reporting on patients with stage 4S neuroblastoma from the trial. In this dataset, there is one row for each stage 4S patient enrolled on the ANBL00B1 biology study, from which eligible patients enrolled to the phase III ANBL0531 study. The variable ANBL0531 in this dataset indicates which patients enrolled to ANBL0531 from the biology study. The dataset also contains MYCN status, ploidy DNA index, baseline characteristics, EFS, and survival data.
SUBJECT_ID is the patient identifier in all datasets.
• NCT00499616-D2 (PMID 30444686): There are five datasets (-D1 through -D5) for the ANBL0531 primary publication 30444686, reporting on patients with stage 4S neuroblastoma from the trial. This dataset contains adverse event data.
• NCT00499616-D3 (PMID 30444686): There are five datasets (-D1 through -D5) for the ANBL0531 primary publication 30444686, reporting on patients with stage 4S neuroblastoma from the trial. This dataset contains 1p and 11q loss of heterozygosity, age at diagnosis and death, cause of death, hepatomegaly, select adverse events at baseline, and number of cycles of therapy data, presented in Table 4 of the publication.
• NCT00499616-D4 (PMID 30444686): There are five datasets (-D1 through -D5) for the ANBL0531 primary publication 30444686, reporting on patients with stage 4S neuroblastoma from the trial. The dataset contains the primary and contributing reasons that patients went off therapy, treatment received, and disease response data.
• NCT00499616-D5 (PMID 30444686): There are five datasets (-D1 through -D5) for the ANBL0531 primary publication 30444686, reporting on patients with stage 4S neuroblastoma from the trial. This dataset contains baseline characteristics, MYCN status, ploidy DNA index, treatment assignment, degree of resection, select baseline adverse events, 1p and 11q loss of heterozygosity, surgery information, and survival data.
• NCT00499616-D6 (PMID 31386611): There are two datasets (-D6 and -D7) for the ANBL0531 primary publication 31386611, reporting on patients with stage 2A/2B or stage 3 neuroblastoma from the trial. This dataset contains baseline characteristics, MYCN status, ploidy category, 1p and 11q loss of heterozygosity, degree of resection, EFS, treatment assignment, surgery information, cycles of treatment received, survival, and cause of death data.
• NCT00499616-D7 (PMID 31386611): There are two datasets (-D6 and -D7) for the ANBL0531 primary publication 31386611, reporting on patients with stage 2A/2B or stage 3 neuroblastoma from the trial. In this dataset, there is one row for each adverse event experienced during cycles 1-8 and retrieval therapy cycles 9-14.
You are encouraged to view the PDF data dictionaries found in the "Documents" tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).
- Type: Interventional
- Archive: The database of Genotypes and Phenotypes (dbGaP)
